{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:02:40Z","timestamp":1781074960191,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diagnosing cardiac sarcoidosis (CS), especially in isolated cases, is challenging, particularly due to the limitations of endomyocardial biopsy, leading to potential undiagnosed cases in pacemaker-implanted patients. This study aims to provide real world findings to support new guideline for CS using 18F-fluoro-deoxyglucose positron-emission tomography computed tomography (FDG-PET\/CT) which give a definite diagnosis of isolated CS (iCS) without histological findings. We examined consecutive patients with cardiac pacemakers for atrioventricular block (AV-b) attending our outpatient pacemaker clinic. The patients underwent periodical follow-up echocardiography and were divided into two groups according to echocardiographic findings: those with suspected CS and those without suspected CS. Patients suspected of having nonischemic cardiomyopathy underwent FDG-PET\/CT for CS diagnosis. We investigated the utility of the new guideline for CS using FDG-PET\/CT. Among the 272 patients enrolled, 97 patients were implanted with cardiac pacemakers for AV-b. Twenty-two patients were suspected of having CS during a median observation period of 5.4\u00a0years after pacemaker implantation. Of these, one did not consent, and nine of 21 cases (43%) were diagnosed with definite CS according to the new guidelines. Five of these nine patients were diagnosed with iCS using FDG-PET\/CT. The number of patients diagnosed with definite CS using the new guidelines tended to be approximately 2.3 times that of the conventional criteria (p\u2009=\u20090.074). Three of the nine patients underwent steroid treatment. The composite outcome, comprising all-cause death, heart failure hospitalization, and a substantial reduction in left ventricular ejection fraction, were significantly lower in patients receiving steroid treatment compared to those without steroid treatment (p\u2009=\u20090.048). The utilization of FDG-PET\/CT in accordance with the new guidelines facilitates the diagnosis of CS, including iCS, resulting in approximately 2.3 times as many diagnoses of CS compared to the conventional criteria. This guideline has the potential to support the early identification of iCS and may contribute to enhancing patient clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-024-58475-z","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:04:56Z","timestamp":1712131496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utility of new FDG-PET\/CT guidelines for diagnosing cardiac sarcoidosis in patients with implanted cardiac pacemakers for atrioventricular block"],"prefix":"10.1038","volume":"14","author":[{"given":"Subaru","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Fukuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"58475_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","volume":"68","author":"DH Birnie","year":"2016","unstructured":"Birnie, D. H., Nery, P. B., Ha, A. C. & Beanlands, R. S. Cardiac sarcoidosis. J. Am. Coll. Cardiol. 68, 411\u2013421 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"58475_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.jcmg.2020.11.016","volume":"14","author":"M Subramanian","year":"2021","unstructured":"Subramanian, M. et al. Pretreatment myocardial (18)FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis. JACC Cardiovasc. Imaging 14, 2008\u20132016 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"58475_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1536\/ihj.17-492","volume":"59","author":"T Kaida","year":"2018","unstructured":"Kaida, T. et al. Importance of early diagnosis of cardiac sarcoidosis in patients with complete atrioventricular block. Int. Heart J. 59, 772\u2013778 (2018).","journal-title":"Int. Heart J."},{"key":"58475_CR4","doi-asserted-by":"publisher","first-page":"e249183","DOI":"10.1136\/bcr-2022-249183","volume":"15","author":"S Tanabe","year":"2022","unstructured":"Tanabe, S., Nakano, Y., Suzuki, Y. & Amano, T. Successful use of stellate ganglion phototherapy in refractory ventricular tachycardia in a patient with cardiac sarcoidosis. BMJ Case Rep. 15, e249183 (2022).","journal-title":"BMJ Case Rep."},{"key":"58475_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jce.12401","volume":"25","author":"PB Nery","year":"2014","unstructured":"Nery, P. B. et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J. Cardiovasc. Electrophysiol. 25, 875\u2013881 (2014).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"58475_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0002-8703(97)70070-X","volume":"134","author":"Y Yoshida","year":"1997","unstructured":"Yoshida, Y. et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am. Heart J. 134, 382\u2013386 (1997).","journal-title":"Am. Heart J."},{"key":"58475_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCHEARTFAILURE.112.000087","volume":"6","author":"MK Bennett","year":"2013","unstructured":"Bennett, M. K. et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000\u20132009. Circ. Heart Fail. 6, 676\u2013684 (2013).","journal-title":"Circ. Heart Fail."},{"key":"58475_CR8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","volume":"83","author":"F Terasaki","year":"2019","unstructured":"Terasaki, F. et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis\u2014Digest version. Circ. J. 83, 2329\u20132388 (2019).","journal-title":"Circ. J."},{"key":"58475_CR9","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1002\/ehf2.12853","volume":"7","author":"H Kawai","year":"2020","unstructured":"Kawai, H. et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail. 7, 2662\u20132671 (2020).","journal-title":"ESC Heart Fail."},{"key":"58475_CR10","first-page":"19","volume":"31","author":"MA Judson","year":"2014","unstructured":"Judson, M. A. et al. The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool. Sarcoidosis Vasc. Diffuse Lung Dis. 31, 19\u201327 (2014).","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"58475_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","volume":"11","author":"DH Birnie","year":"2014","unstructured":"Birnie, D. H. et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 11, 1305\u20131323 (2014).","journal-title":"Heart Rhythm."},{"key":"58475_CR12","first-page":"89","volume":"27","author":"The Japan Society of Sarcoidosis and Other Granulomatous Disorders","year":"2007","unstructured":"The Japan Society of Sarcoidosis and Other Granulomatous Disorders, The Diffuse Pulmonary Study Group of the Health and Labor Sciences Research Grant-Supported Rare\/Intractable Disease Project. Diagnostic standard and guideline for sarcoidosis 2006. J. Sarcoidosis Granulomatous Disord. 27, 89\u2013102 (2007).","journal-title":"J. Sarcoidosis Granulomatous Disord."},{"key":"58475_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-022-03034-0","author":"T Okada","year":"2022","unstructured":"Okada, T. et al. Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET\/CT. J. Nucl. Cardiol. https:\/\/doi.org\/10.1007\/s12350-022-03034-0 (2022).","journal-title":"J. Nucl. Cardiol."},{"key":"58475_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","volume":"138","author":"A Uemura","year":"1999","unstructured":"Uemura, A. et al. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am. Heart J. 138, 299\u2013302 (1999).","journal-title":"Am. Heart J."},{"key":"58475_CR15","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/heartjnl-2022-320932","volume":"108","author":"T Kitai","year":"2022","unstructured":"Kitai, T. et al. Comparisons between biopsy-proven versus clinically diagnosed cardiac sarcoidosis. Heart 108, 1887\u20131894 (2022).","journal-title":"Heart"},{"key":"58475_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacasi.2021.09.005","volume":"1","author":"K Kusano","year":"2021","unstructured":"Kusano, K. et al. Prognosis and outcomes of clinically diagnosed cardiac sarcoidosis without positive endomyocardial biopsy findings. JACC Asia 1, 385\u2013395 (2021).","journal-title":"JACC Asia"},{"key":"58475_CR17","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/eurheartj\/ehi180","volume":"26","author":"S Ishimaru","year":"2005","unstructured":"Ishimaru, S. et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur. Heart J. 26, 1538\u20131543 (2005).","journal-title":"Eur. Heart J."},{"key":"58475_CR18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jacc.2005.01.047","volume":"45","author":"JP Smedema","year":"2005","unstructured":"Smedema, J. P. et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J. Am. Coll. Cardiol. 45, 1683\u20131690 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"58475_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamacardio.2022.2981","volume":"7","author":"PSS Athwal","year":"2022","unstructured":"Athwal, P. S. S. et al. Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis. JAMA Cardiol. 7, 1057\u20131066 (2022).","journal-title":"JAMA Cardiol."},{"key":"58475_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjcard.2022.06.040","volume":"180","author":"A Yamamoto","year":"2022","unstructured":"Yamamoto, A. et al. Adverse cardiac events in cardiac sarcoidosis prediction by 123I-betamethyl-p-iodophenyl-pentadecanoic acid single-photon emission computed tomography and cardiac magnetic resonance late gadolinium enhancement. Am. J. Cardiol. 180, 149\u2013154 (2022).","journal-title":"Am. J. Cardiol."},{"key":"58475_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3056","author":"D Maeda","year":"2023","unstructured":"Maeda, D. et al. Clinical characteristics and prognosis of patients with isolated cardiac sarcoidosis: Insights from the ILLUMINATE-CS study. Eur. J. Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3056 (2023).","journal-title":"Eur. J. Heart Fail."},{"key":"58475_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2303\/jecho.5.1","volume":"5","author":"T Yamano","year":"2007","unstructured":"Yamano, T. & Nakatani, S. Cardiac sarcoidosis: What can we know from echocardiography? J. Echocardiogr. 5, 1\u201310 (2007).","journal-title":"J. Echocardiogr."},{"key":"58475_CR23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s12350-019-01755-3","volume":"26","author":"S Kumita","year":"2019","unstructured":"Kumita, S. et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J. Nucl. Cardiol. 26, 1414\u20131433 (2019).","journal-title":"J. Nucl. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58475-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58475-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:08:47Z","timestamp":1712131727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58475-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["58475"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-58475-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.N. reported receiving lecture fees from Ono Pharma Co., Ltd., AstraZeneca, Otsuka Pharma Co., Ltd., Nihon Medi-Physics Co., Ltd., and Novartis Pharma Co., Ltd.; T.A. reported receiving lecture fees from Astellas Pharma Co., Ltd., AstraZeneca, Daiichi Sankyo, Otsuka Pharma Co., Ltd., Nihon Medi-Physics Co., Ltd., and Novartis Pharma Co., Ltd. Other authors do not have any conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7825"}}